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Targeted therapy for patients with HER2-positive (HER2+) breast cancer
has improved overall survival, but many patients still suffer relapse and
death from the disease. Intratumor heterogeneity of both estrogen receptor
(ER) and HER2 expression has been proposed to play a key role in treat-
ment failure, but little work has been done to comprehensively study this
heterogeneity at the single-cell level. In this study, we explored the clinical
impact of intratumor heterogeneity of ER protein expression, HER2 pro-
tein expression, and HER2 gene copy number alterations. Using combined
immunofluorescence and in situ hybridization on tissue sections followed
by a validated computational approach, we analyzed more than 13 000 sin-
gle tumor cells across 37 HER2+ breast tumors. The samples were taken
both before and after neoadjuvant chemotherapy plus HER2-targeted
treatment, enabling us to study tumor evolution as well. We found that
intratumor heterogeneity for HER2 copy number varied substantially
between patient samples. Highly heterogeneous tumors were associated
with significantly shorter disease-free survival and fewer long-term sur-
vivors. Patients for which HER2 characteristics did not change during
treatment had a significantly worse outcome. This work shows the impact
of intratumor heterogeneity in molecular diagnostics for treatment selection
in HER2+ breast cancer patients and the power of computational scoring
methods to evaluate in situ molecular markers in tissue biopsies.
Abbreviations
BAC, bacterial artificial chromosome; CAP, College of American Pathologists; Cent, centromere; CN, copy number; CR, complete response;
ER, estrogen receptor; FEC, fluorouracil, epirubicin, and cyclophosphamide; FFPE, formalin-fixated paraffin-embedded; FISH, fluorescence
in situ hybridization; HER2amp, amplified HER2 copy number; HER2gain, gain HER2 copy number; HER2, human epidermal growth factor
receptor 2; HER2norm, normal HER2 copy number; IntClust, integrated cluster; K-L, Kullback–Leibler divergence score; pCR, pathological
complete response; PgR, progesterone receptor; RECIST, The Response Evaluation Criteria In Solid Tumors; SI, Shannon index.
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1. Introduction
Breast cancer is divided into several distinct subtypes,
and the expression level of estrogen receptor (ER),
progesterone receptor (PgR), and human epidermal
growth factor receptor 2 (HER2) is fundamental for
treatment decision and prognosis of the disease. The
HER2-positive (HER2+) tumors account for 15–20%
of all breast cancers and are characterized by either
overexpression of HER2 protein and/or increased copy
number of the HER2 gene. With the introduction of
HER2-targeted therapy, such as trastuzumab and
lapatinib, the overall survival for both early- and
late-stage disease has increased (Baselga et al., 2012;
Cortazar et al., 2014; Gianni et al., 2010; Guarneri
and Conte, 2004; Viani et al., 2007).
Breast cancer was one of the first solid cancer types
where comprehensive molecular profiling revealed
robust molecular subtypes (Curtis et al., 2012; Perou
et al., 2000), and HER2+ tumors are found within sev-
eral subtypes. By PAM50 classification, HER2+
tumors are mainly found in the HER2-enriched but
also in the luminal B and luminal A subtypes (Parker
et al., 2009). Similarly, in the 10 integrated cluster
(IntClust) subtypes, the HER2+ tumors dominate
group 5 but are also found within other subtypes (Cur-
tis et al., 2012). The notion that HER2+ tumors do
not represent a separate subtype but a wider biological
spectrum was strengthened by a recent study identify-
ing four different subtypes of HER2+ breast carcino-
mas based on gene expression signatures (Ferrari
et al., 2016).
Pathologists have noticed the presence of cell-to-cell
variation in HER2+ tumors since the introduction of
biomarkers into diagnostic routine. In early-stage
HER2+ breast cancer, neither the average level of
HER2 protein expression nor the average level of
HER2 gene amplification across a tumor seem to have
an impact on therapy response (Wolff et al., 2013;
Zabaglo et al., 2013). However, as reflected by the
comprehensive College of American Pathologists
(CAP) guidelines, some HER2+ tumors display intra-
tumor variation in HER2 copy number (HER2 CN)
levels. The ASCO/CAP guidelines from 2013 state that
breast cancers with aggregations of HER2-amplified
cells (with HER2/CEP17 ratio > 2.0 or more than six
HER2 copies per cell) in more than 10% of the tumor
must be quantified and reported separately (Wolff
et al., 2013). The clinical challenge of such a definition
has been addressed for HER2 equivocal cases (Bartlett
et al., 2011; Lewis et al., 2005), but the clinical impact
of intratumor heterogeneity within nonequivocal
HER2+ tumors is less studied (Arena et al., 2013; Gul-
bahce et al., 2016). The regional variation of HER2
gene amplification has been studied to some extent
(Lee et al., 2014; Seol et al., 2012), and heterogeneity
of HER2 CN even in tumors classified as nonamplified
was recently described (Buckley et al., 2016), but there
are very few studies addressing this at the single-cell
level estimating multiple biomarkers from a high num-
ber of cells.
To investigate and quantify the heterogeneity of
HER2+ carcinomas by using single cell investigation,
we performed detailed in situ analyses on samples
from a Norwegian observational study (RA-HER2),
comprised of 37 HER2+ patients treated in a neoadju-
vant setting with trastuzumab and chemotherapy
where both response data and clinical follow-up were
available. For objective assessment of the molecular
in situ markers, we used GOIFISH, a software for image
analysis developed to objectively score both
immunofluorescence and FISH signals from numerous
individual tumors cells (Trinh et al., 2014). With this
quantitative approach, we examined 103 images and
more than 13 000 cells showing the clinical impact of
different types of genomic and phenotypic intratumor
heterogeneity in HER2+ breast cancer.
2. Materials and methods
2.1. Patient samples
Breast cancer patients diagnosed with HER2+ tumors
between 2004 and 2010 who qualified for neoadjuvant
treatment according to the national guidelines were
included in this prospective observational trial.
Informed and written consent was obtained from all
patients, and the study was approved by the Regional
Ethical Committee (South-east of Norway, no. S-
06495b). The study methodologies conformed to the
standards set by the Declaration of Helsinki.
The clinical characteristics are shown in Table S1.
All 37 patients received combinatorial neoadjuvant
treatment of four cycles of fluorouracil, epirubicin,
and cyclophosphamide (FEC) followed by four cycles
of taxanes in combination with the HER2-targeted
monoclonal antibody trastuzumab. The average
neoadjuvant treatment period was 6 months (range 3–
10 months). The Response Evaluation Criteria In
Solid Tumors (RECIST) (Nishino et al., 2010) was
used to score the effect of the neoadjuvant treatment,
with pathological complete response (pCR) defined as
no invasive tumor cells in primary tumor region or
lymph nodes after neoadjuvant treatment. Non-pCR
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was defined as the presence of residual invasive tumor
cells in primary tumor region or lymph nodes
(Table S1). After neoadjuvant treatment, 12 patients
had pathological complete response (pCR), and among
the 25 patients with noncomplete pathological
response (non-pCR), a variation in tumor reduction
from almost complete response to no reduction in
tumor size was observed (Table S1).
Formalin-fixated paraffin-embedded (FFPE) tumor
tissue from the 37 patients was collected from several
hospitals throughout Norway. FFPE core needle biop-
sies from the time of diagnosis and FFPE surgical
biopsies after neoadjuvant treatment were available for
analysis. In addition, FFPE tissue biopsies from later
distant metastases were available for three patients.
2.2. IFISH analyses
The FISH probes for HER2 were made from the BAC
clones RP11-94L15 and RP11-909L6, and FISH
probes for centromere 17 (cent17) were made from
BAC clones RP11-170N19 and RP11-909L10. The
BAC probes were isolated according to the instruc-
tions from the manufacturer and labeled with fluores-
cent UTPS by nick translation. Primary antibody
recognizing estrogen receptor (clone 6G11) was
detected with secondary antibody IgG-conjugated
Alexa Fluor 594. The HER2 (CB11) primary antibody
was detected with a secondary biotinylated antibody
and visualized using streptavidin-conjugated Alexa
Fluor 488 antibody in order to visualize the protein
expression of ER and HER2. A detailed IFISH proto-
col including antibody and BAC catalogue numbers is
described in the previous publication (Trinh et al.,
2014). The tissue samples were mounted with DAPI
counterstain, and areas of interest were photographed
with 25 z-stacks in a Zeiss Axiovision M1 microscope.
The areas with a high number of tumor cells and with
high quality of IFISH staining were selected for pho-
tography. The number of biopsies, areas, and tumor
cells analyzed per sample are listed in Table S2.
2.3. Analysis by GOIFISH
We previously developed and validated the software
GOIFISH (Trinh et al., 2014), an image analysis pipeline
designed to objectively recognize cell types, score pro-
tein intensities in distinct cellular compartments (nu-
cleus, cytoplasm, and membranes), count and measure
FISH spots/areas and intensities, measure nuclear size,
and display topological distributions of the cells and
the analyzed parameters. GOIFISH estimates are highly
concordant with visual scoring at the single-cell level,
and optimal intensity thresholds of 300 and 50 follow-
ing adjustment by background and perinuclear
intensity were used to define HER2-positive and ER-
positive cells, respectively, from 12-bit images (Trinh
et al., 2014). ER+ patients were identified according to
the national guidelines with a cutoff level at 1% posi-
tive cells (Helsedirektoratet 2014). The HER2 copy
number (HER2 CN) level was assessed by measuring
the total area of the HER2 probe signals within each
nucleus. For cluster analyses to study phenotypic
heterogeneity, we assigned each cell within a tumor
into one of four phenotypic groups (HER2+/ER+,
HER2+/ER, HER2/ER+, HER2/ER) based on
the defined thresholds. To address heterogeneity based
on genomic changes, we assigned each cell into one of
three HER2 CN categories as previously defined
(Trinh et al., 2014): normal (HER2norm), gain
(HER2gain) or amplified (HER2amp). HER2norm
reflected cells with up to three spots (0–63 pixels),
HER2gain: three to six spots (64–200 pixels), and
HER2amp: > 6 spots (> 200 pixels). Additionally, we
considered the combined effect of both phenotype and
genotype and classified each cell into one of twelve
groups: HER2+/ER+ HER2 amp, HER2+/ER+ HER2
gain, HER2+/ER+ HER2 norm, HER2+/ER HER2
amp, HER2+/ER HER2 gain, HER2+/ER HER2
norm, HER2/ER+ HER2 amp, HER2/ER+ HER2
gain, HER2/ER+ HER2 norm, HER2/ER HER2
amp, HER2/ER HER2 gain, or HER2/ER
HER2 norm.
Five samples were excluded in comparisons between
pre- and post-treatment samples: three due to low
numbers of tumor cells present after neoadjuvant ther-
apy, and two samples had insufficient IFISH staining
due to technical problems [immunofluorescence and
genomic (FISH) analyses were performed separately].
2.4. Spatial distribution of HER2 amplification
within tumor nuclei
Three spatial patterns of HER2 FISH signals within
individual tumor cell nuclei were identified by visual
inspection. Cells demonstrating a tight cluster of multi-
ple signals were called ‘cluster’, cells with distinct and
separate signals were called ‘scatter’, and those with
both patterns were annotated as ‘mix’. The HER2 spa-
tial distribution pattern was scored in 100 tumor cells
from each biopsy (from both pre- and post-treatment
samples) and in the three samples from metastases.
These single-cell scores were collapsed to the patient
level by (a) computing the frequency of each pattern
and (b) using a 70% majority cutoff to describe a class
for each patient. If a tumor did not show one
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particular dominant pattern, it was considered as
‘heterogeneous’. In the pretreatment samples, 10 were
dominated by ‘cluster’ cells, six with ‘mix’, eight with
‘scatter’, and 13 samples were ‘heterogeneous’ with
regard to spatial patterns.
2.5. Statistical analyses
The Welch t-test was used to determine differences in
intensity distributions, and Fisher’s exact t-test was
used to calculate the differences between groups of
patients. Survival curves were constructed using the
Kaplan–Meier method, using both disease-free survival
(i.e., time to metastasis) and overall breast cancer-spe-
cific survival as events. Differences in survival between
groups of patients were studied by univariate cox
regression analyses and expressed as hazards ratios
with 95% confidence intervals using continuous vari-
ables. The Shannon index (SI) was used as measure
for heterogeneity of the defined phenotypic and geno-
mic groups and combined phenotypic and genomic
groups (Shannon, 1948), and the mean Shannon index
for each cluster group was used to determine the dif-
ferences in heterogeneity between clusters.
To measure the change in the clonal composition
during neoadjuvant therapy, the Kullback–Leibler
divergence index (K-L) (Kullback and Leibler, 1951)
was used to compare the cell-type distributions before
and after treatment. Briefly, this describes the diver-
gence between two populations, such as the phenotypic
composition of pre- and post-treatment samples:
K-L ¼ 
XM
i
Pi log
Qi
Pi
where Pi is the proportion of cells which belong to
group i in the pretreatment group and Qi is the pro-
portion of cells which belong to group i in the post-
treatment samples. M indicates the number of discrete
groups considered: four for phenotypic change, three
for genomic changes, and 12 for the combined change.
A high index signifies different clonal compositions in
the samples taken after treatment versus the samples
taken before. The median of the Kullback–Leibler
index was used to divide the samples into two equal
sized groups: one group with samples with a high
change of HER2 CN fractions (K-L high) and one
group with samples with low change in fractions (K-L
low).
All image analysis was performed in MATLAB (7.12.0
(R2011a), The MathWorks, Natic, MA, USA), and
subsequent statistical analyses were performed in R (R
Core Team, 2017). All code to reproduce the analyses
in this study is available at the following Github Link/
as supplementary information https://github.com/trin
han/HER2heterogeneity.
3. Results
We analyzed more than 13 000 single tumor cells from
biopsies taken before treatment (n = 37), after treat-
ment (n = 22) and metastases (n = 3) from 37 HER2-
positive (HER2+) breast cancer patients. Single-cell
metrics for HER2 and ER expression, HER2 copy
number, and CEP17 copy number were evaluated.
This enabled us to evaluate the heterogeneity of the
markers both across tumors but also within the indi-
vidual tumors at different time points, as illustrated in
Fig. 1A–D. As an example, images of pre- and post-
treatment biopsies from patient 7588 show the protein
and FISH staining of the tumor cells. The GOIFISH soft-
ware was used to visualize the spatial distribution of
cells with different phenotypic and/or genotypic fea-
tures, as shown in Fig. 1E,F where each cell is pseudo-
colored with regard to HER2 and ER protein expres-
sion. Changes in cell populations during therapy are
evident; prior to therapy, the tumor had both HER2+/
ER+ and HER2+/ER cells, while in the post-treat-
ment tumor, a new dominant population of HER2/
ER+ cells emerged. The phenotypic change during
therapy is further illustrated in Fig. 1G, where each
dot represents a tumor cell and the color illustrates the
phenotype. Furthermore, there was a substantial
reduction of cells with high HER2 CN after treatment,
reflected in Fig. 1G by the size of each dot.
3.1. Intertumor heterogeneity within HER2+
tumors
All images were subjected to the same analyses as for
the case shown in Fig. 1, and a substantial variation
of marker distribution was seen across the cohort. This
is visualized in the compilation of representative
images from each of the 37 pretreatment samples
shown in Fig. S1. To get a first overview of the cohort,
we estimated the mean values of the biomarkers (i.e.,
measurements from all tumor cells within a sample)
and found patients with nonpathological complete
response (non-pCR) to have a significantly lower mean
copy number of the HER2 gene compared to patients
with pathological complete response (pCR) (Fig. S2A,
t-test: P = 0.02). No significant difference in mean
HER2 and ER protein expression was found. By look-
ing at the same biomarkers and stratifying the patients
by disease progression, we found a significantly lower
ER expression (P = 0.02) and lower HER2 CN/cent17
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A B E
C D F
G
Fig. 1. IFISH images reflecting intratumor heterogeneity before and after treatment. Expression of ER and HER2 protein and copy number
of HER2 gene by IFISH (color code below images) for (A) pretreatment biopsy from patient #7588, (B) magnified image of the outlined area,
(C) post-treatment biopsy of patient #7588, and (D) magnified image of the outlined area. Pseudo-colored cell phenotypes of (E)
pretreatment biopsy (same area as in A), (F) post-treatment biopsy (same area as in C). (G) Tumor cell heterogeneity before and after
treatment for patient #7588, and the scatter plot shows the relationship between ER expression (X-axis) and HER2 expression (Y-axis) for
each of the individual cells. The color reflects the cell phenotype. The size of the dot reflects each cells HER2 CN level, where a small dot
equals fewer copies and a large dot more copies of the HER2 gene.
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CN ratio (P = 0.009) in samples from patients with
later metastatic disease compared to those without
metastasis (Fig. 2A). Figure 2B illustrates the pretreat-
ment cell-type composition in an ER-negative tumor
with highly amplified HER2 CN from a patient which
later had progressive disease. The cell composition in
an ER-positive tumor with gained HER2 CN from a
patient who has not had progressive disease is shown
in Fig. 2C.
Using 1% positive cells as a cutoff level from GOI-
FISH, we identified 28 patients with ER-positive (ER+)
tumors (76%) and nine patients with ER-negative
(ER) tumors (24%). Complete response to neoadju-
vant treatment was seen in 7/28 (28%) and 5/9 (55%)
patients with ER+ and ER tumors, respectively.
With regard to metastasis, 9/28 (32%) patients with
ER+ and 3/9 (33%) patients with ER tumors devel-
oped metastasis (Table S1). Tumors were stratified into
four groups based on the percentage of ER+ cells pre-
sent: ER-negative (< 1%, n = 9), low ER (1–10%,
n = 9), intermediate ER (10–50%, n = 10), and high
ER (> 50%, n = 9). Although not significant, a trend
that patients with low or intermediate number of ER+
cells had less local response to treatment was observed,
as well as a worse prognosis compared to those with
either high-ER or ER-negative tumors (Fig. S2B).
We next sought to determine whether relationship
between ER and HER2 protein expression and HER2
copy number at single-cell level could influence patient
outcome. As illustrated by scatterplots in Fig. S3, sub-
stantial variation was seen with regard to ER and
HER2 protein expression both across tumors and
within tumors. In addition, some tumors showed a lin-
ear relationship between HER2 CN and HER2 protein
level, but others did not (Fig. S4). In addition, we
noticed that the relationship could change during ther-
apy (Figs S3 and S4).
To address the clinical implication of this protein
variation, we assigned each cell to one of four cate-
gories: HER2+/ER+, HER2+/ER, HER2/ER+, or
HER2/ER (see Materials and methods section). By
comparing the fractions of cells with different pheno-
types, subsets of tumors with distinct types of pheno-
typic intratumor heterogeneity were identified.
*
= =
0
# #
*
**
**P = 0.009
P = 0.015
A
B C
Fig. 2. Biomarker status and later
progression of disease. (A) Comparison of
GoIFISH measurements (HER2 copy
number (HER2 CN), cent17, ratio (HER2
CN/cent17), ER protein expression, and
HER2 protein expression) for all
pretreatment biopsies (n = 37) stratified
by relapse or not after neoadjuvant
treatment (Wilcox t-test). (B) IFISH image
from a patient with later relapse of
disease (#7360). The cells were ER,
HER2+ with amplification of HER2 (same
color scheme as in Fig. 1A–D). (C) IFISH
image from a patient without later relapse
of the disease (#7362). The sample was
ER+, HER2+ with gain of HER2 copies.
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Hierarchical clustering of the fractions of each cell class
revealed three separate groups of tumors. Group P1
contained tumors dominated by HER2+/ER+ cells,
while tumors in the cluster group P2 was dominated by
HER2+/ER cells (Fig. 3A and Table S3). IFISH
images from two patients representing phenotypic clus-
ters P1 and P2 are shown in Fig. 3B. Patients in cluster
group P2 had tumors with negative to intermediate ER
expression and were associated with high histological
grade (Table S3). They also had a higher frequency of
later metastasis, and the Kaplan–Meier curves indicated
a worse prognosis, although this was not significant
(Fig. 3C, Fig. S5A). Interestingly, P2 was the least
heterogenous cluster with a Shannon index (SI) of 0.34,
compared to P1 which had SI = 0.66 (Table S4). Cluster
group P3 only contained three samples, all dominated
by HER2-negative tumor cells. Two of these samples
were scored 2+ by IHC (#7619 and #7441); the third
sample (#7370) had one HER2-positive and one HER2-
negative biopsy prior to therapy.
In contrast to cellular phenotypes, where subpopula-
tions can be dynamic and cells might change
A
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Fig. 3. Identification of subsets of HER2+ breast cancer patients by phenotypic diversity. (A) Unsupervised cluster analysis of the fractions
of the phenotypic cell types HER2/ER, HER2+/ER, HER2/ER+, and HER2+/ER+ in the pretreatment samples (n = 37) where the
percentage of each cell type (i.e., fraction) is indicated by the color intensity. Two large clusters and one small were identified, where
cluster group P1 (n = 11) was dominated by HER2+/ER+ cells and cluster group P2 was dominated by HER2+/ER- cells. The smallest
cluster group contained three patients whose tumors had mainly HER2 cells. The clinical information for each patient is illustrated by the
boxes next to the dendrogram. (B) IFISH image to the left is from pretreatment biopsy from patient #6739 (in cluster group P1) which was
dominated by HER2+/ER+ tumor cells. The image to the right is from the pretreatment sample from patient #7641 (cluster group P2)
dominated by HER2+/ER tumor cells. (C) Survival analyses; breast cancer-specific death for the two groups (P = 0.24). D) Survival
analyses; breast cancer-specific death between patients with different percentage of ER+ cells (P = 0.14, log-rank test).
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expression levels rapidly in response to treatment,
HER2 copy number (CN) will reflect more persistent
cellular subclones. We categorized each cell into one of
three levels of HER2 CN (norm, gain, and amp) and
determined the cellular composition of each tumor (see
Materials and methods section). We found some
tumors to be dominated by cells with similar copy
number level, while other tumors had more heteroge-
neous cellular composition. Hierarchical clustering
identified three groups of tumors with different levels
of HER2 genomic heterogeneity (Fig. 4A, Table S4).
The most distinct difference between these three
groups was the fraction of cells with HER2 amplifica-
tion. The smallest group of tumors (cluster group G1,
n = 6) had overall low-level HER2 CN with few cells
with HER2amp and the highest heterogeneity
(SI = 1.2). The second largest group (cluster group
G2, n = 13) had tumors mainly dominated by cells
with HER2amp and had a low degree of heterogeneity
(SI = 0.6). This was in contrast to the third group
(cluster group G3, n = 16), which had a high fraction
of HER2amp cells, but also fractions of HER2gain
and HER2norm cells and overall a high degree of
heterogeneity (SI = 0.9). A representative image of
each cluster group is shown in Fig. 4B. Interestingly,
the patients belonging to cluster G3 displaying high
intratumor variation but with HER2amp dominating
were more likely to experience distant metastases
(Table S3) and had the highest risk of disease progres-
sion (HR: 14.9, P: 0.04, Fig. 4C) but not a signifi-
cantly increased risk of death by breast cancer
(Fig. 4D). However, the groups were not distinguished
by other clinical parameters; in particular we were not
able to find any significant correlation with treatment
response measured by tumor reduction (Table S3).
To investigate the impact of combined phenotypic
and genomic heterogeneity, we next assigned each cell
within a tumor to one of twelve combined phenotypic–
genomic (PG) groups (see Materials and methods sec-
tion). Three separate groups were identified (Fig. S5A),
where cluster PG1 (n = 9) was comprised of highly
heterogeneous tumors containing both ER+ and ER
cells with varying HER2 CN levels (amp, gain, and
norm) (SI = 1.8). Cluster PG2 (n = 8) consisted pre-
dominantly of tumors with ER+/HER2+ cells with
HER2amp (SI = 1.28). The largest group, cluster PG3
(n = 20), was also dominated by cells with HER2amp
with predominantly a ER/HER2+ phenotype, but
many tumors had cells with normal levels or gain of
HER2 CN (SI = 0.99). Patients in PG2 had > 50% ER+
cells, all had high HER2 protein expression (3+), and
none had later progression of the disease (Table S3).
Although not significant, a trend was observed where
patients in the PG1 and PG3 groups had a higher risk of
progressive disease and breast cancer-related death than
patients in group PG2 (Fig. S5B,C).
3.2 The HER2 spatial organization
During visual investigation of the images, we noticed
different spatial patterns of HER2 amplifications within
each nucleus. Some cells had a tight cluster of multiple
signals, others had fewer signals scattered within the
nucleus and some had a combination (Fig. 5A, see
Materials and methods section for more details). We
named the nuclear spatial patterns ‘cluster’, ‘scatter’,
and ‘mix’. As intratumor heterogeneity with regard to
HER2 CN levels seemed to have prognostic informa-
tion, we wanted to address whether the observed differ-
ences in spatial organization of the HER2 gene was of
clinical importance. As shown in the triangle plots in
Fig. 5B, we observed intertumor variation where some
samples were dominated by one spatial type (samples in
the corners of the triangle plot in Fig. 5B), while others
had a more heterogeneous distribution, illustrated by
being plotted towards the centre of the triangle. A sig-
nificant difference in the distribution of samples from
patients with and without pathological complete
response (pCR) was observed; samples from patients
with pCR were most frequently of ‘cluster’ or ‘mix’
type, while samples from patients with non-pCR were
more heterogeneous and dominated the group charac-
terized by the ‘scatter’ type of distribution (Fisher’s
exact test, P = 0.007, Table S5A). We found an indica-
tion for patients with tumors dominated by ‘mixed’ spa-
tial type not to have disease progression, in contrast to
patients with tumors dominated by ‘cluster’ or with a
combination of the three types (Fig. 5C, Fig. S6A,
Table S5B). Interestingly, these spatial distributions
were also associated with ER status: ER-negative
tumors were found to be frequently of ‘cluster’ or ‘mix’
spatial type (Fig. S6B, Table S5C) when stratifying the
ER-positive samples into negative, low (1–10%), inter-
mediate (10–50%), and high ER (> 50%). The interme-
diate ER+ tumors were predominantly of the ‘scatter’
spatial type, while the ER-negative and ER-low tumors
(P = 0.007) were predominantly of the ‘cluster’ spatial
type (Fig. 5D, Table S5D).
3.3. Predicting disease progression by
measurements of clonal shift during therapeutic
intervention
As patients with more heterogeneous tumors (reflected
both by ER status and by cellular subclones displaying
different types of HER2 CN) had a higher risk of
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Fig. 5. The spatial organization of the HER2 gene copies within the nuclei. (A) Each cell was categorized as ‘cluster’, ‘scatter’, and ‘mixed’
based on the spatial organization of the HER2 gene within the nuclei. (B) The spatial organization for the HER2 CN for the pretreatment
samples (n = 37); in the triangle plot, each corner represents homogenous cell population (100% of cells have one of the spatial patterns).
Samples from patients with complete response are colored in blue and from patients with noncomplete response are colored in red
(Fisher’s exact test, P = 0.007). C) Kaplan–Meier curve for time to disease progression for the categorized spatial organization ‘cluster’,
‘mix’, ‘scatter’, and the ‘< 70%’ groups. D) The spatial organization for the pretreatment samples where samples are colored by ER
expression level (percentage of positive cells). ER-negative samples are colored in red, ER low (1–10%) colored in green, ER intermediate
(10–50%) colored in blue, and ER high (> 50%) colored in yellow (Fisher’s exact test, P = 0.007).
Fig. 4. Identification of subsets of HER2+ breast cancer patients by HER2 copy number diversity. (A) Unsupervised clustering based on the
fractions of cells with different levels of HER2 copy number (normal, gain, or amplified). Three clusters (G1–G3) were identified. The clinical
information for each patient is illustrated in the boxes next to the dendrogram. (B) FISH (HER2 CN) images from patient samples
representing each of the three cluster groups (G1–G3). The top image is from cluster G2 (patient #6450) and shows a tumor dominated by
HER2 CN amp cell type, the second image is from cluster G3 (patient #7379) and shows a sample with an intermediate fraction of cells
with HER2 CN amp, and the last image is from cluster G1 (#7619) and shows a sample with a high fraction of HER2 CN gain and a low
fraction of HER2 CN amp cell types. (C) Survival analyses showed significant differences in risk for progression between the two groups
(P = 0.008, log-rank test) but not for breast cancer-specific death (D).
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relapse, we next studied the population dynamics, that
is, which cell types did or did not respond to therapy
and whether dynamics during therapy can reveal
patients with better prognosis or not. We assessed
change in tumor composition in 20 patients who did
not achieve complete pathological response. To objec-
tively address the dynamics of cell populations during
neoadjuvant treatment, we calculated changes in frac-
tions of the predefined cell types (phenotypic and
HER2 CN and the combined phenotypic/HER2 CN
cell types) before and after therapy using the
Kullback–Leibler (K-L) divergence index. Figure 6A
illustrates the change in HER2 CN cell types (delta
calculated by comparing fractions before and after
therapy) sorted according to decreasing K-L index.
Patients with low K-L index had a significantly
increased risk of breast cancer-related death compared
to patients with high K-L index, indicating that
patients with smaller changes in subpopulations of
cells during treatment actually have worse long-term
outcome (Fig. 6B, P = 0.035). There was no correla-
tion to any other clinicopathological parameters,
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Fig. 6. Tumor evolution during neoadjuvant treatment. (A) The Kullback–Leibler diversity index (K-L index) was calculated reflecting changes
in cells with different levels of HER2 CN during therapy. The samples were sorted from high to low K-L index, and the changes of the
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(patient #7588) and from a patient with low K-L index (patient #7435).
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including degree of pathological response (Table S6).
Figure 6C shows IFISH images (HER2 CN) from
samples taken before and after therapy for two
patients. Patient #7588 who did not have progression
of the disease showed a decrease in the fractions of
cells with HER2amp, while patient #7435 who devel-
oped progression of the disease did not show any
changes in the HER2 CN cell types during therapy. In
contrast, there was neither any association between
patient outcomes with phenotypic changes nor with
combined phenotypic/HER2 changes based on the K-
L index (Fig. S7A,B).
With regard to the individual markers analyzed,
we did not observe any significant changes in the
global levels of HER2 and cent17 CN level nor in
the HER2 and ER protein intensity in tumors after
neoadjuvant treatment (Fig. S7C). In particular, we
did not observe a significant difference between
patients with a high shift of phenotype or combined
phenotypic/HER2 CN status compared to those with
a low shift with regard to survival of disease or
treatment outcome.
3.4. Diversity in primary tumor versus metastasis
Sampling of tumor metastases was not included in the
study protocol, but tissue biopsies from distant metas-
tases were available from three of the patients (two
patients with noncomplete response and one patient
with complete response to therapy). IFISH images of
biopsies from three time points (pre- and post-treat-
ment and later distant metastasis) of two of the
patients are shown in Fig. 7A–F. Patient #7435
(Fig. 7A–C) had a primary tumor dominated by
HER2+/ER cells with HER2 CN amplification. After
neoadjuvant treatment, we found an increase in cells
with HER2+/ER+ phenotype. Interestingly, the biopsy
from a metastasis showed the same cell phenotypes as
the pretreatment tumor. There was no evidence of clo-
nal shift as the samples from all three time points were
dominated by cells with HER2 CN amplification
(Fig. 7G). In contrast, the tumor from patient #7360
(Fig. 7D–F) had prior to treatment mainly HER2+/
ER cells, but the biopsy after treatment and from
the metastasis revealed a small fraction of HER2/
ER cells. There was only a minimal change in the
fraction of cells with HER2 CN amplification
(Fig. 7H). We also investigated the spatial organiza-
tion of the HER2 CN at the three time points, and
both samples had a more similar spatial pattern for
the HER2 CN for the pretreatment and metastatic
lesion in contrast to the post-treatment biopsy, but the
changes were only minor (Fig. 7I,J).
4. Discussion
Analysis of tumor samples taken from patients during
neoadjuvant treatment is extremely useful for studying
the clinical impact of tumor cell diversity. The signifi-
cance of intratumor heterogeneity for treatment
response can be measured by comparing molecular
features of tumor cells from pre- and post-treatment
biopsies. As in situ methods only allow us to measure
a small number of markers, we chose the clinically
most important biomarkers, namely ER (protein) and
HER2 (protein and gene copy number). Even with so
few biomarkers, the combined IFISH technique
revealed a high diversity both between tumors but
also within tumors (i.e., cell-to-cell variation). It is
known that tumors classified as HER2+ by immuno-
histochemistry (i.e., 3+) can have different levels of
HER2 amplification by ISH techniques. Our work
supports this observation but also provides a higher
resolution as all markers are studied simultaneously in
thousands of individual cells. We found remarkable
diversity, with regard to the expression of both ER
and HER2 proteins as well as for HER2 CN on a sin-
gle-cell level (Figs S1, S3, and S4). It was intriguing to
find some tumors with a linear correlation between
the two proteins and/or between protein and HER2
CN, while others were not linear. Next, we aimed at
investigating whether the type of diversity was truly
individual or whether there were patterns of intratu-
mor heterogeneity shared by subsets of tumors.
Performing comparative studies of intratumor hetero-
geneity in sample collections is challenging. Major
hurdles are the continuous level of expression/copy
number changes per cell, each cell having different
combinations of expression/copy number changes, and
each tumor having different numbers of cells mea-
sured. We therefore chose to categorize the data (by
using a threshold for each marker and then assigning
each cell into distinct subpopulations) and were thus
able to compare the cellular composition across the
tumors. Interestingly, when we ‘simplified’ the com-
plex cellular information this way, we actually found
that there are subsets of tumors with similar cell-type
composition. Both by classifying each cell into pheno-
typic and genomic predefined categories and by per-
forming three separate clustering analyses, we found
the groups not only having differences in clinical out-
come but also in several other interesting features.
For instance tumors of patients with a higher risk for
disease progression and/or breast cancer-related death
have: (a) high expression of HER2 but low or inter-
mediate number of ER+ cells (P2 in Fig. 3), (b) a mix-
ture of cells with different HER2 CN levels (G3 in
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Fig. 4), and (c) a mixture of cells with different HER2
CN levels with low number of ER+ cells (PG3 in
Fig. S5). Combined, these findings indicate that
patients with tumors dominated by HER2-amplified
cells and with homogenous ER expression (either neg-
ative or positive) have a good long-term prognosis. It
also indicates the importance of addressing not only
the heterogeneity of HER2 CN but also the variation
in ER expression in HER2+ breast carcinomas. In the
work by Ferrari et al. (2016), HER2+ tumors were
split into four groups based on gene expression pat-
terns, and the level of ER expression varied between
them. Although the study did not address intratumor
heterogeneity, it clearly showed that a subgroup of
HER2+ carcinomas was composed of ER-negative
tumors, one subgroup of highly ER-positive tumors,
and two subgroups of tumors with more intermediate
ER levels. It will be of interest to see the follow-up
studies of this cohort with outcome data as well. In a
recent study, approximately 30% of patients with
neoadjuvant-treated HER2+ tumors (chemotherapy
and HER2-targeted treatment) achieved pathological
complete response (pCR), but this fraction was lower
for patients with HER2+ and ER+ tumors, but the
level of ER positivity was not addressed (Cortazar
et al., 2014). In a study by Romond et al. (2005),
patients with ER+ tumors had a lower response rate
to treatment, but this seems to be mainly restricted to
those with tumors having < 50% ER-positive tumor
cells. These findings are in line with ours; patients
with heterogeneous ER expression had a tendency
toward a reduced long-term survival (Fig. 3). Carey
et al. recently published results from the
CALGB40601 trial, which also shows that local
response varies between ER+ and ER subtypes of
HER2+ breast cancer (Carey et al., 2016). We found
no evidence that the HER2 protein intensity level has
impact on local response, which is in line with the
observation by Zabaglo et al. (2013) but contradicts
the CALGB 40601 trial which found gene expression
levels of both ER and HER2 to be correlated with
pCR rates (Carey et al., 2016).
In our study, we find HER2 CN level to be of clini-
cal importance as the level in pretreatment samples
was significantly higher in tumors from responders
compared to nonresponders. This is in line with previ-
ous studies showing high levels of HER2 amplification
to be associated with pathological complete response
(pCR) (Arnould et al., 2007) (Guiu et al., 2010)
although HER2 CN level could not predict long-term
disease progression or survival. This is supported by
studies of anti-HER2 treatment in adjuvant setting
where HER2 CN level has shown no or negative corre-
lation with disease-free survival (Xu et al., 2016). As
mentioned previously, HER2 CN heterogeneity seems
to have an impact on prognosis in our study. We
found tumors with heterogeneous composition with
regard to HER2 CN level to have higher risk of
relapse and breast cancer-specific death (patients in G3
group in Fig. 4). Some studies indicate the same result
in less advanced stage of the disease; in a study of
adjuvant-treated HER2+ breast cancer, Seol et al.
(2012) found regional heterogeneity in HER2 CN to
predict a worse survival. The study by Lee et al.
(2014) also found patients with both regional and
genomic heterogeneity of HER2 amplification to have
decreased disease-free survival, but neither of these
two study cohorts had uniform treatment regimens
(Seol et al., 2012). Kurozumi et al. studied variation in
both HER2 copy number and HER2 protein expres-
sion within tumors using a semi-objective analysis
(with visual scoring) and found that regional variation
of HER2 CN reflected a worse prognosis particularly
in ER-negative disease (Kurozumi et al., 2016). Unfor-
tunately, these patients had not received anti-HER2
therapy, so neither the predictive value nor the impact
of dynamics during therapy could be addressed.
One of the most striking findings in our study was
the large number of tumors exhibiting intratumor vari-
ation with regard to HER2 CN levels. As copy num-
ber alterations are inherited in daughter cells, we
believe these populations to reflect true subclones that
have undergone different paths of evolution. The clus-
ter analysis based on HER2 CN levels showed that
patients with tumors dominated by cells with amplified
HER2 gene had a significantly better survival com-
pared to the patients with more heterogeneous HER2
amplification levels (Fig. 4). Patients in the latter
Fig. 7. Intratumor heterogeneity during disease progression. IFISH images from biopsies from patient #7435 (with a magnified area to the
right): (A) pretreatment biopsy, (B) post-treatment biopsy, and (C) biopsy from a metastasis. Equally from patient #7360: (D) pretreatment
biopsy, (E) post-treatment biopsy, and (F) biopsy from metastasis (Dapi = blue, HER2 = green, ER = red, HER2 = yellow, and
cent17 = cyan). The phenotype and HER2 CN level for all tumor cells analyzed from each of the three biopsies are plotted in the diagram
(G) patient #7435 and (H) patient #7360 (colored due to their phenotypic cell type and the size of the spot reflect the HER2 copy number
level). Spatial organization of the HER2 gene visualized in a triangle for the pre-treatment (red square), post-treatment (green circle), and
metastatic (blue triangle) sample from patient #7435 (I) and patient #7360 (J).
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group (cluster G3 in Fig. 4) had tumors with a mixed
cellular composition. These patients had a significantly
shorter time to progression of the disease and fewer
long-term survivors. We suggest that patients belong-
ing to cluster group G3 represent cases similar to those
described by Ballard et al. (2017) as ‘nonclassical’
HER2 FISH results.
Changes in ER and HER2 status are observed for
some cases during neoadjuvant treatment, and this
change seems to affect protein expression (i.e., pheno-
type) more than HER2 copy numbers (Van de Ven
et al., 2011). However, studies of genomic and pheno-
typic intratumor heterogeneity of HER2+ breast carci-
nomas and their impact on treatment resistance have
been scarce. A recent study of HER2+ tumors at the
single-cell level found overexpression of BRF2 and
DSN1 as genomic driver events in HER2-negative cells
(Ng et al., 2015). This indicates a presence of subpop-
ulations that can explain treatment resistance. It has
also been shown that that important genetic driver
events such as PIK3CA mutation and HER2 gene
amplification are not always present within the same
cell (Janiszewska et al., 2015). As minor subclones
might need time to proliferate and progress (by clonal
selection), this could explain why we find heteroge-
neous tumors to have a significantly increased risk for
disease progression regardless of the initial local
response. When comparing intratumor heterogeneity
before and after treatment, we were surprised to find
that patients in the group with no changes in the cellu-
lar composition had an increased risk for later pro-
gression of the disease. One explanation for this
finding could be that none of the tumor subclones
were affected by the treatment and probably reflecting
tumors where HER2 gene amplification is not the
important driver. Another explanation could be treat-
ment resistance due to ligand-independent activation
of HER2 (Yarden, 2001) rather than selection of
clones proliferating independently of HER2 activity.
Interestingly, these tumors do not reflect the situation
identified by Ng et al. (2015) where a HER2-negative
subpopulation could be suspected to explain therapy
resistance. Our study was unfortunately not suitable
for next-generation sequencing (NGS)-based identifica-
tion of driver events in resistant subclones and more
detailed explorative studies to identify alternative can-
didate drivers will be needed. Identification of distinct
genomic alterations related to the cellular dynamics
during treatment might provide clinicians with more
therapy options for such patients.
Finally, the cases with samples from three time
points showed intriguing results; the pretreatment and
metastatic lesion had a more similar spatial pattern for
the HER2 CN in contrast to the post-treatment biopsy
(Fig. 7I,J). One of the cases showed a major switch in
phenotype (Fig. 7A–C) but had a very low Kullback–
Leibler index, reflecting minor influence of treatment
on HER2 CN cell types. The other case had only a
minor phenotype change, and the HER2 CN cell types
did not shift enough to be reflected by the Kullback–
Leibler index. Although this is just case observation, it
reflects breast cancer to be a disease that can evolve
along different paths with regard to both phenotypic
and genomic/clonal composition.
An important challenge for estimating intratumor
heterogeneity is the need for objective measurements of
molecular biomarkers. Buckley et al. (2016) proposed a
simple heterogeneity index for HER2 CN heterogene-
ity, but this was based on visual counting of 20 cells (as
defined by the CAP guidelines) by an observer. To
address potential observer bias and maximize the num-
ber of analyzed cells, we estimated heterogeneity by
objective assessment of HER2 CN of more than 13 000
cells using GOIFISH, an image analysis software that can
omit artificial staining and specifically characterize
tumor cells for further analysis. Still, tissue artifacts
such as incomplete tumor cell nuclei due to sectioning
can influence the results. We also used cluster analyses
of the fractions of cell types within a tumor; thus, the
presence of some misclassified cells will not influence
the results substantially. Finally, the visual categoriza-
tion of intranuclear spatial distributions of the HER2
amplicon also reflected the presence of different types of
genomic disruptions and amplification mechanisms,
representing a different way of assessing clonal hetero-
geneity. Here, we analyzed fewer cells per sample (100
cells), but the finding is in line with other studies (by
DNA sequencing) showing that HER2 gene amplifica-
tions can be a result of different types of DNA rear-
rangement mechanisms (Morganella et al., 2016). This
cohort does not have tumor material suitable for NGS
analyses of this kind, but this is important to address in
suitable sample collections.
This study is based on a neoadjuvant observational
trial, comprising of HER2+ patients for which
matched primary, post-treatment, and, in some cases,
metastatic samples were available for analysis. The
strength of this cohort lies in the strict inclusion crite-
ria and consistency in terms of treatment regimens,
allowing us to make direct comparisons between
patient samples and track the cellular dynamics
throughout the treatment process. Although this study
could benefit from an increased patient sample size
and sufficient patient material to conduct DNA
sequencing analysis, this observational cohort has
nonetheless offered an insight on the wide biological
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spectrum within HER2+ breast carcinomas and in par-
ticular the negative association between HER2 CN
intratumoral heterogeneity and patient outcome.
5. Conclusion
This is to our knowledge the first study of breast cancer
revealing cellular heterogeneity with regard to HER2
expression, HER2 copy number, and ER expression
through analysis of a substantial number of cells from
neoadjuvant-treated HER2+ breast cancer patients.
HER2+ disease is highly heterogeneous both between
and within tumors. The heterogeneity of ER expression
as well as HER2 copy number variation seems to have
impact on disease progression and survival. Addition-
ally, tumors with preserved level of HER2 CN hetero-
geneity during therapy (i.e., cell-type composition
before and after therapy) had a poor prognosis. The
study shows the importance of assessing cell-to-cell
variation both prior to treatment and during treatment,
and consequential population shifts to predict response
to therapy. It also shows the importance of having an
objective analysis of multiple markers in a high number
of cells facilitated by automatized image analysis. The
challenge now is not only to validate the clinical impact
of molecular subtypes within HER2+ breast cancer
patients but also to address the cellular variation within
the tumors in more depth.
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